Weekly injection therapy for gMG wins US, EU approval as Klygefa
Drug's use led to 'meaningful improvements' in daily living, per developer
Written by |
The once-weekly therapy gefurulimab has been approved in both the U.S. and the European Union as a treatment for generalized myasthenia gravis. (Image from iStock)
- Advocates on two continents are welcoming the approval, in both the U.S. and the EU, of Klygefa for generalized myasthenia gravis.
- The weekly injection therapy was cleared for treating adults and children with gMG who have anti-acetylcholine receptor antibodies.
- Developer Alexion, AstraZeneca Rare Disease called Klygefa "a first-of-its-kind treatment for gMG," noting its autoinjector delivery device.
Regulators in both the U.S. and the European Union have approved the injection therapy gefurulimab for adults with generalized myasthenia gravis (gMG) who are among the approximately 85% of patients positive for antibodies against the acetylcholine receptor (AChR) protein.
The Alexion, AstraZeneca Rare Disease therapy — to be marketed under the brand name Klygefa — works by suppressing C5, a protein involved in the abnormal immune responses that drive gMG.
While other gMG-approved therapies also target C5, Klygefa is the first to offer a once-a-week regimen that can be self-administered under the skin (subcutaneously) using an autoinjector — a device that delivers the drug into the body at the touch of a button.
“The US approval of Klygefa delivers a first-of-its-kind treatment for gMG that offers the efficacy of C5 [suppression] with the flexibility of once-weekly subcutaneous self-administration via autoinjector,” Marc Dunoyer, CEO of Alexion, said in a company press release announcing the U.S. approval. Per the developer, the drug’s use in a large, late-stage clinical trial led to “statistically significant and clinically meaningful improvements in activities of daily living starting as early as week one and sustained through one year.”
Dunoyer added: “We … look forward to soon delivering this pioneering innovation to adults with gMG in the US.”
In a separate company press release announcing the European approval, Dunoyer said that the drug’s clearance in the EU also “marks an important milestone for the gMG community” across that continent, noting that the treatment “combines the proven efficacy and safety of C5 inhibition” with a potentially more convenient dosing regimen.
In myasthenia gravis (MG), self-reactive antibodies disrupt communication between nerve and muscle cells, leading to symptoms such as muscle weakness and fatigue. Anti-AChR antibodies are the most common drivers of both MG and gMG, in which weakness extends beyond the muscles controlling the eyes and eyelids. When these antibodies bind to AChR, it activates a group of immune proteins called the complement cascade, which triggers tissue damage.
Klygefa works by blocking activation of the complement cascade by inhibiting the complement protein C5. It’s also designed to remain in the body for longer periods of time.
Three C5-targeting treatments, also called C5 inhibitors, are already approved for AChR-related gMG in the U.S. and Europe. Two of them, Ultomiris (ravulizumab-cwvz) and Soliris (eculizumab), are sold by Alexion and are administered by infusion into the bloodstream, which needs to be done under the supervision of a healthcare professional. A third therapy, UCB’s Zilbrysq (zilucoplan), is given by subcutaneous injection, which can be self-administered by patients at home, but must given once daily.
Klygefa approvals mainly based on clinical trial findings
By offering a self-administered option that only needs to be injected once weekly, Klygefa aims to offer more convenience while retaining the same disease-controlling abilities as these other C5 inhibitors, its developer notes.
“Klygefa reflects our continued commitment to advancing innovation in ways that respond to the diverse needs of people living with this complex and unpredictable disease,” said Scott Weintraub, senior vice president, head of U.S. business at Alexion.
Klygefa’s approvals were mainly based on data from the global Phase 3 PREVAIL clinical trial (NCT05556096), which tested the therapy against a placebo in 260 adults with AChR-related gMG.
The results showed Klygefa outperformed the placebo at reducing scores on the MG Activities of Daily Living and Quantitative MG scales, two standard assessments of disease severity.
“The PREVAIL Phase [3] trial demonstrated the ability of [Klygefa] to deliver rapid and durable disease control starting as early as week one and lasting through one year, with the added autonomy of once-weekly subcutaneous self-administration,” said Tobias Ruck, MD, a trial investigator at BG University Hospital Bergmannsheil Bochum in Germany.
The most commonly reported adverse events among patients given Klygefa in PREVAIL were injection site reactions, according to the developer.
As with other C5 inhibitors, the therapy’s U.S. prescribing information includes a boxed warning — the U.S. Food and Drug Administration’s most stringent safety precaution — noting that the medication may increase risk of certain serious infections. Due to this risk, the therapy will only be available in the U.S. through a restricted risk evaluation and mitigation strategy program. Information about that program is available at www.KlygefaREMS.com or by calling 1-888-765-4747.
gMG advocates welcome new treatment option
Approvals of Klygefa in the U.S. and Europe were applauded by advocates on both continents.
“Because no two patients experience gMG in the same way, expanding the range of options available is fundamental to how we improve lives,” said Samantha Masterson, president and CEO of the Myasthenia Gravis Foundation of America (MGFA). “The MGFA welcomes this approval and the new possibilities it opens for those who have been seeking more independence and greater control of their treatment administration.”
“Every new treatment option brings renewed hope and the possibility of finding approaches that work better for more people living with this disease. … That’s what makes me hopeful.
Lutgarde Allard, president of the European Myasthenia Gravis Association, said the EU approval “signifies more than scientific progress; it gives us hope and demonstrates that our community’s needs are being heard.”
Allard added: “For people across Europe living with this rare condition, the approval of this new medicine means more choice, convenience and the potential to regain independence in daily life.”
In a statement from the Muscular Dystrophy Association (MDA), Elizabeth Madole, a youngster living with gMG who serves as an MDA Ambassador, echoed these sentiments.
“Every new treatment option brings renewed hope and the possibility of finding approaches that work better for more people living with this disease,” Madole said. “And for a kid like me, that could mean getting through a whole day of school and still having enough energy to hang out with my friends afterward. That’s what makes me hopeful.”
Klygefa is also approved in Japan. Other regulatory submissions are “under review in China and additional countries,” according to the developer.
Leave a comment
Fill in the required fields to post. Your email address will not be published.